NewswireToday - /newswire/ -
Hoboken, NJ, United States, 2014/05/01 - John Wiley & Sons, Inc., today announced the launch of Evidence Based Preclinical Medicine (EBPM) as part of the Wiley Open Access publishing program - EvidenceBasedPreclinicalMedicine.com / WileyOpenAccess.com. NYSE: JWa, JWb
EBPM is the first journal dedicated to publishing systematic review protocols and systematic reviews which summarise data from animal studies on subjects relevant to human health.
“As the publisher of The Cochrane Library, the launch of EBPM consolidates Wiley’s position as the leading publisher in evidence-based medicine,” said Rachel Burley, Vice President and & Director Open Access. “EBPM will introduce the same level of rigour to reviewing research evidence that is already widely accepted in the health science community to preclinical science.”
Systematic reviews are a form of meta-analysis to identify, appraise, select and synthesize all high quality research evidence relevant to a specific question. EBPM’s synthesis of preclinical evidence will improve evaluation of the potential success in future clinical trials, providing transparent and accurate reporting of research studies and improving the reliability and value of medical research. While systematic reviews are well established in the health sciences, they are not prevalent within life sciences.
"Evidence Based Preclinical Medicine (evidencebasedpreclinicalmedicine.com) aims to be more than just a journal" said Co-Editor-in-Chief Professor Malcolm Macleod. "By providing a foundation of pre-clinical evidence we can escape the enthusiasms and vested interests that can distort the application of research from animals to humans."
The journal has developed a helpdesk to guide practitioners through the processes of systematic review and to help authors prepare their study datasets for publication. In addition to the reviews, the journal publishes protocols describing the proposed approach for a systematic review enabling readers to distinguish between hypothesis and evidence-based observations.
EBPM requires that all datasets supplementary to the reviews be held in a public repository. By providing tools to access these datasets, the journal will ensure that information collected in the context of systematic reviews will be publicly available.
The journal is edited by Associate Professor David Howells, co-division head of the stroke division at The Florey Institute of Neuroscience and Mental Health, and Professor Malcolm Macleod, whose team at the University of Edinburgh has led the development and application of systematic review and meta-analysis of animal studies modelling stroke.
About Wiley Open Access
Wiley Open Access (wileyopenaccess.com) provides authors wishing to publish their research outcomes in an open access journal with a range of high quality publications which meet the requirements of funding organisations and institutions where these apply. Wiley Open Access journals are supported by a network of high-quality journals and societies as well as internationally-renowned editorial board members.
Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.
Founded in 1807, John Wiley & Sons, Inc. (wiley.com), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia.